Compared to the 375 individuals prescribed a GLP-1 RA for diabetes or obesity indications, those not on GLP-1 RA treatment had over twice the risk of all-cause mortality (adjusted HR: 2.3; 95% CI: 1.4–3.6) and a 1.7 (95% CI: 1.2–2.5) times greater hazard of progression to decompensated cirrhosis.55 This evidence concerns the gene GLP1R and Cirrhosis.